Eli Lilly and Novo Nordisk Set to Compete in Oral Obesity Drug Market
Eli Lilly and Novo Nordisk, two giants in the pharmaceutical industry, are gearing up for a significant showdown in the realm of obesity medications. Both companies are on the verge of launching oral versions of their popular GLP-1 (glucagon-like peptide-1) drugs in the United States, a move that could reshape the landscape of weight-loss treatments. As the obesity epidemic continues to escalate, these oral medications may offer a more accessible option for millions of Americans seeking effective weight management solutions.
